- /
- Supported exchanges
- / US
- / SPRY.NASDAQ
ARS Pharmaceuticals, Inc (SPRY NASDAQ) stock market data APIs
ARS Pharmaceuticals, Inc Financial Data Overview
ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes treatments for severe allergic reactions in the United States and internationally. The company is involved in the development of neffy, a needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with ARS Pharmaceuticals, Inc (top by weight)
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get ARS Pharmaceuticals, Inc data using free add-ons & libraries
Get ARS Pharmaceuticals, Inc Fundamental Data
ARS Pharmaceuticals, Inc Fundamental data includes:
- Net Revenue: 117 M
- EBITDA: -214 646 000
- Earnings Per Share: -2
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
Get ARS Pharmaceuticals, Inc Earnings data
Corporate Events Calendar & News package for
What’s included:
- Latest Release: 2026-11-05
- EPS/Forecast: -0.34
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
ARS Pharmaceuticals, Inc News
New
ARS Pharmaceuticals, Inc. (SPRY) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
ARS Pharmaceuticals, Inc. (SPRY) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended September 2026. This widely-known consens...
ARS Pharma to Report Third Quarter 2026 Financial Results
ARS Pharmaceuticals, Inc. SAN DIEGO, Oct. 28, 2026 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a commercial biopharmaceutical company dedicated to empowering at-risk patients and th...
ARS Pharmaceuticals to Participate in Upcoming Investor Conferences
ARS Pharmaceuticals, Inc. SAN DIEGO, Sept. 01, 2026 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregi...
ARS Pharma (SPRY) Cuts Spending As It Chases Neffy Market Share
On August 13, ARS Pharmaceuticals (NASDAQ:SPRY) held its second-quarter 2026 earnings call, the first for new President and CEO Donn Casale. He used it to lay out three priorities: sharper commercial ...
Corporate Events Calendar & News package for
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.